| Market Capitalization (Millions $) |
992 |
| Shares
Outstanding (Millions) |
195 |
| Employees |
19 |
| Revenues (TTM) (Millions $) |
191 |
| Net Income (TTM) (Millions $) |
161 |
| Cash Flow (TTM) (Millions $) |
-13 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is a biotechnology company headquartered in Warminster, Pennsylvania, United States. The company has a focus on developing novel therapeutics that address hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and other liver diseases.
Their lead product candidate, AB-729, is a potentially first-in-class RNA interference (RNAi) therapeutic targeting HBV surface antigen, with the aim of achieving sustained virologic responses in patients. The drug utilizes Arbutus' proprietary GalNAc delivery technology, which is designed to specifically deliver RNAi agents to hepatocytes, the primary liver cells responsible for HBV replication.
Arbutus Biopharma operates a fully integrated research and development center in Burnaby, British Columbia, Canada, which includes chemistry and bioanalytical laboratories, as well as manufacturing facilities for clinical and commercial production of its drug products. The company has a strong intellectual property portfolio consisting of a variety of patents and patent applications that cover its drug candidates, delivery technologies and manufacturing processes.
The company has collaborations with a number of other biotech and pharmaceutical companies, including Roivant Sciences and Gritstone Oncology, aimed at developing RNAi therapies for the treatment of a variety of diseases. Arbutus also collaborates with the Baruch S Blumberg Institute, a renowned research institute based in Doylestown, Pennsylvania, to discover and develop new drug candidates for the treatment of liver diseases.
Arbutus Biopharma was founded in 2005 and went public in 201 The company is traded on the NASDAQ Global Market under the ticker symbol "ABUS".
Company Address: 701 Veterans Circle Warminster 18974 PA
Company Phone Number: 469-0914 Stock Exchange / Ticker: NASDAQ ABUS
|
99.79 %